Skip to Main Content

Paper Details

A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study.
Neuro Oncol
63
2021
ALT, ARRY-142886, AST, AZD6244, Brain Tumor, CPK, MEK-1/2, NF1, OPHGs, PBTC-029, Pediatric, Pediatric Brain Tumor, Pediatric low-grade gliomas, Selumetinib, anemia, brain tumor, childhood, children, diarrhea, emesis, fatigue, headache, hypoalbuminemia, nausea, neurofibromatosis type 1, optic pathway and hypothalamic gliomas, optic pathway and hypothalamic low-grade glioma, pLGGs, patients, rash, selumetinib, visual deficits
Author NameAffiliation
Jason FangusaroChildren's Healthcare of Atlanta and Emory University
Tina Young PoussaintSt. Jude Children's Research Center
Tina Young PoussaintBoston Children's Hospital
Azra H LigonBrigham and Women's Hospital, Harvard Medical School
Anuradha BanerjeeCenter for Cancer and Blood Disorders, University of California san francisco
Sridharan GururanganUniversity of Florida
Lindsay KilburnDivision of Oncology Children's National Hospital
Lindsay KilburnDivision of Oncology Children's National Hospital
Stewart GoldmanChildren's National Hospital
Stewart Goldman
Patricia BaxterAnn and Robert H. Lurie Children's Hospital of Chicago
Patricia BaxterTexas Children's Hospital
Corey Bregman
Michael J FisherNationwide Children's Hospital
Michael J FisherThe Children's Hospital of Philadelphia
Malcolm A SmithClinical Investigation Branch, National Cancer Institute and Cancer Therapy Evaluation Program
Malcolm A SmithClinical Investigation Branch, National Cancer Institute and Cancer Therapy Evaluation Program
Maryam FouladiDepartment of Hematology and Oncology Nationwide Children's Hospital
  • 1 - 18

Datasets

Release 1.2